secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalo Therapeutics, Inc. (AVTX)
CIK:        0001534120
Form:       8-K
Filed at:   2025-03-26T23:59:59+00:00
Accession:  0001628280-25-014833
Event type: leadership
Sentiment:  positive
Materiality: 0.55
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avalo Therapeutics appoints Michael Heffernan as Chairman, separating roles from CEO Garry Neil
--------------------------------------------------------------------------------

- Michael Heffernan appointed Chairman of the Board, effective March 25, 2025; succeeds Dr. Garry Neil who remains CEO and Board member.
- Heffernan brings experience building biopharma companies and executing exits; will guide pipeline including AVTX-009 in Phase 2 LOTUS trial for HS.
- Company states sufficient capital to achieve potentially transformative data readout from LOTUS trial next year.
- Board also approved Amended and Restated Non-Employee Director Compensation Plan to attract and retain qualified directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534120/000162828025014833/0001628280-25-014833-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534120/000162828025014833/avtx-20250325.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-014833

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer